BPC-157 vs B7-33

BPC-157 and B7-33 are research peptides with distinct origins and therapeutic targets. BPC-157 is a 15-amino-acid fragment of human gastric juice protein, studied extensively in animal models for tissue repair—spanning tendons, ligaments, muscle, bone, nerves, gastrointestinal mucosa, and vasculature. Its evidence base is robust in preclinical contexts but limited in human trials. B7-33, in contrast, is a single-chain analog of human relaxin-2, engineered to activate the RXFP1 receptor with simplified manufacturing. Preclinical studies suggest vasodilatory and anti-fibrotic properties, positioning it for cardiovascular and fibrotic disease research. The peptides share no direct mechanistic overlap, making selection dependent on specific research goals: BPC-157 for broad regenerative studies, B7-33 for targeted cardiovascular or fibrotic investigations.

BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; MW ~1419.5 g/mol) is a synthetic peptide derived from a protein in human gastric juice. Its mechanism is multifaceted, involving upregulation of growth factors (e.g., VEGF, EGF), modulation of nitric oxide synthase, and stabilization of the cytoskeleton, which collectively promote angiogenesis, cell migration, and tissue regeneration. Evidence is drawn from hundreds of animal studies demonstrating accelerated healing in tendon, ligament, muscle, bone, nerve, and gastrointestinal injuries. However, human clinical data remain sparse: only three pilot studies as of 2025 (knee pain, n=16; interstitial cystitis, n=12; IV safety, n=2). The FDA classifies BPC-157 as Category 2 (significant safety concerns), prohibiting compounding, though it was removed from this category on April 15, 2026, pending PCAC review in July 2026. WADA bans its use in sports. Researchers should weigh its robust preclinical promise against the lack of rigorous human safety data.

B7-33 is a single-chain analog of human relaxin-2, designed to retain RXFP1 receptor activation while simplifying synthesis. Relaxin-2 is a two-chain hormone with vasodilatory and anti-fibrotic effects, mediated through RXFP1 binding, which triggers nitric oxide production and matrix metalloproteinase activity. B7-33's simplified structure reduces manufacturing costs and complexity, making it a practical tool for preclinical research. Evidence is limited to animal models and in vitro studies, showing vasodilation in vascular tissues and reduced fibrosis in cardiac, renal, and hepatic models. No human clinical trials have been completed, and the peptide's safety profile is uncharacterized in humans. Its mechanism is narrower than BPC-157, targeting specific pathways rather than broad regenerative processes. Researchers investigating cardiovascular protection or fibrotic disease may find B7-33 a focused alternative, but its evidence base is less mature than BPC-157's.

BPC-157 and B7-33 target distinct research domains with minimal overlap. BPC-157 is primarily studied in injury recovery—tendon, ligament, muscle, bone, and nerve healing—and gastrointestinal health, including protection against NSAID-induced damage and leaky gut. Its applications span regenerative medicine and gastroenterology. B7-33, conversely, is focused on cardiovascular protection (vasodilation, blood pressure regulation) and anti-fibrotic effects in organs like the heart, kidneys, and liver. The only shared area is potential tissue repair, but through different mechanisms: BPC-157 promotes broad regenerative cascades, while B7-33 targets specific receptor-mediated pathways. Researchers should select based on the system under investigation—musculoskeletal or gastrointestinal for BPC-157, cardiovascular or fibrotic for B7-33.

Safety profiles for both peptides are based on preclinical data, with no completed human clinical trials for either. For BPC-157, animal studies across multiple species (mice, rats, dogs) found no toxic or lethal dose thresholds at ranges from 6 mcg/kg to 20 mg/kg; LD1 was not achieved. Necropsy and histopathology showed no teratogenic, genotoxic, or anaphylactic effects. However, the FDA previously classified BPC-157 as Category 2 due to significant safety concerns, including insufficient human safety data and potential immunogenicity risks. It was removed from Category 2 on April 15, 2026, with PCAC review pending July 2026 to determine compounding eligibility. For B7-33, no human safety data exist; theoretical risks include hypotension due to its vasodilatory mechanism. Researchers should exercise caution, particularly with B7-33, given its uncharacterized human safety profile.